RECENT PUBLICATIONS:
Phan, H-D., Li J., Poi, M*. and Nakanishi, K. (2018) Quantification of miRNAs Co-immunoprecipitated with Argonaute Proteins Using SYBR Green-Based qRT-PCR. InArgonaute Proteins: Methods and Protocols, Methods in Molecular Biology, vol. 1680:29-40, Springer Publishing, New York, in press. *Co-corresponding author.
Saito, YD., Harris, P., Poi, M., Wesolowski, R (2017). Dose Modification and Use ofAncillary Treatments in Investigational Studies in Clinical Trials. In Background and Introduction to Oncology Clinical Trials, Springer Publishing, New York, in press.
Sborov DW, Cho YK, Cottini F, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, Phelps MA, Hofmeister CC. G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leuk Lymphoma. 2017Dec;58(12):2947-2951. doi: 10.1080/10428194.2017.1318436. Epub 2017 May 16. PubMed PMID: 28509594.
Poi MJ, Knobloch TJ, Li J. Deletion of RD(INK4/ARF) enhancer: A novel mutation to”inactivate” the INK4-ARF locus. DNA Repair (Amst). 2017 Jun 24;57:50-55.doi:10.1016/j.dnarep.2017.06.027. [Epub ahead of print] Review. PubMedPMID:28688373.
Khandoobhai A, Poi M, Kelley K, Mirtallo J, Lopez B, Griffith N. National survey of comprehensive pharmacy services provided in cancer clinical trials. Am J Health Syst Pharm. 2017 Jun 1;74(11 Supplement 2):S35-S41. doi:10.2146/ajhp160628. PubMed PMID: 28506975.
Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma. 2017 Mar 7:1-9. doi: 10.1080/10428194.2017.1298751. [Epub ahead of print] PubMed PMID: 28270022.
Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC. Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol Carcinog. 2017 Feb 2. doi: 10.1002/mc.22626. [Epub ahead of print] PubMed PMID: 28150872.
Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clin Pharmacol Ther. 2017 Feb 4. doi: 10.1002/cpt.644.[Epub ahead of print] PubMed PMID: 28160288.
Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen CS, Kulp SK. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Exp Toxicol Pathol. 2016 Oct;68(9):505-515. doi: 10.1016/j.etp.2016.08.001.
Li Q, Liu Z, Kolli S, Wetz K, Griffith N, Poi MJ. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions. Am J Health Syst Pharm. 2016 Sep1;73(17):1331-7. doi: 10.2146/ajhp150581. PubMed PMID: 27543577.
Jamieson GC, Fox JA, Poi M, Strickland SA. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs. 2016 Sep;76(13):1245-55. doi: 10.1007/s40265-016-0614-z. Review. PubMed PMID: 27484675.
Poi MJ, Knobloch TJ, Sears MT, Warner BM, Uhrig LK, Weghorst CM, Li J. Alterations in RD(INK4/ARF) -mediated en bloc regulation of the INK4-ARF locus in human squamous cell carcinoma of the head and neck. Mol carcinog. 2015; 54(7):532-42. NIHMSID: NIHMS599501 PubMed [journal] PMID: 24302590, PMCID: PMC4102663.
Awan FT, Jones JA, Maddocks K, Poi M, Grever MR, Johnson A, Byrd JC, Andritsos LA. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. Ann Hematol. 2016 Jun;95(7):1137-43. doi: 10.1007/s00277-016-2683-1.
Jaime-Ramirez AC, McMichael EL, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, LaPerle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri M, Lee RJ, Carson WE 3rd. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin are Enhanced by Cytokines. Cancer Immunol Res. 2016 Feb 10. pii: canimm.0168.2015. [Epub ahead of print] PubMed PMID: 26865456.
Christian, B., Poi, M., Jones, JA., Porcu, P., Maddocks, K., Flynn, JM., Benson Jr., DM., Phelps, MA., Wei, L., Byrd, LC., Wegener, WA., Goldenberg, DM., Baiocchi, RA., Blum, KA. Combination of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, Demonstrates Activity in Patients with Relapsed and Refractory B-Cell Non-Hodgkin’s Lymphoma. Br J Haematol. 2015 Apr 7. doi:10.1111/bjh.13354.
Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y,Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA. A doseescalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leuk Res. 2014 Sep;38(9):1025-9. doi:10.1016/ j.leukres.2014.05.011. Epub 2014 May 29. PubMed PMID: 25082342.
Poi MJ, Knobloch TJ, Sears MT, Uhrig LK, Warner BM, Weghorst CM, Li J. Coordinatedexpression of cyclin-dependent kinase-4 and its regulators in human oral tumors. Anticancer Res. 2014 Jul;34(7):3285-92. PubMed PMID: 24982332; PubMed CentralPMCID: PMC4183149.
Poi MJ, Drosdeck J, Frankel WL, Muscarella P, Li J. Deletions of RDINK4/ARF enhancerin gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. Pancreas. 2014 Oct;43(7):1009-13. doi: 10.1097/MPA.0000000000000165. PubMed PMID:25003221.
Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M,Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MA. Erlotinib in African Americans with advanced non-small cell lung cancer: aprospective randomized study with genetic and pharmacokinetic analyses. Clin Pharmacol Ther. 2014 Aug;96(2):182-91. doi: 10.1038/clpt.2014.93. Epub 2014 Apr29.PubMed PMID: 24781527; PubMed Central PMCID: PMC4180036.
Hofmeister CC, Poi M#, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S,Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC. A phase I trial of flavopiridol inrelapsed multiple myeloma. Cancer Chemother Pharmacol. 2014 Feb;73(2):249-57. doi:10.1007/s00280-013-2347-y. Epub 2013 Nov 16. PubMed PMID: 24241210; PubMedCentral PMCID: PMC3946636. #Co-first author.
Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6polymorphisms affecting alternative splicing and transcription: long-range haplotypeswith two regulatory variants modulate CYP2D6 activity. Hum Mol Genet. 2014 Jan1;23(1):268-78. doi: 10.1093/ hmg/ddt417. Epub 2013 Aug 28. PubMed PMID:23985325; PubMed Central PMCID: PMC3857955.
Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA,Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. Flavopiridol can be safelyadministered using a pharmacologically derived schedule and demonstrates activity inrelapsed and refractory non-Hodgkin’s lymphoma. Am J Hematol. 2014 Jan;89(1):19-24.doi: 10.1002/ajh.23568. Epub 2013 Sep 30. PubMed PMID: 23959599; PubMed CentralPMCID: PMC4150545.
Poi, MJ., Knobloch, TJ., Yuan, C., Tsai, M-D., Weghorst, CM., and Li, J (2013). Evidence thatP12, a specific variant of P16INK4A, plays a suppressive role in human pancreatic carcinogenesis. Biochem Biophys Res Commun. 2013;436:217-22. doi:10.1016/ j.bbrc.2013.05.078. Epub 2013 May 29. PMID: 23727582.
Ji, J., Mould, D., Blum, K., Ruppert, A., Poi, M., Zhao, Y., Johnson, A., Byrd, J., Grever, M., andPhelps, AM. Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome inChronic Lymphocytic Leukemia Patients Treated with Flavopiridol. Clin Cancer Res. 2013Mar 1;19(5):1269-80. doi: 10.1158/1078-0432.CCR-12-1092. Epub 2013 Jan 8. PMID:23300276.
Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, DaltonJT, Devine SM, Grever MR, Phelps MA. Standard pentostatin dose reductions in renalinsufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet. 2013 Aug; 52(8):705-12. doi: 10.1007/s40262-013-0064-7. PubMed PMID: 23588536; PubMed Central PMCID: PMC3720841.
Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E,Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent topaclitaxel shortage: a case series and literature review. Support Care Cancer. 2013Oct;21(10):2679-86. doi: 10.1007/s00520-013-1842-3. Epub 2013 May 19. PubMedPMID: 23686402; PubMed Central PMCID: PMC3769512.
ALL PUBLICATIONS:
https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/45266779/?sort=date&direction=descending